International Journal of Inflammation / 2013 / Article / Tab 3

Clinical Study

Cost Effectiveness of TNF- Inhibitors in Rheumatoid Arthritis

Table 3

Resulting ICERs in terms of improvement in the HAQ.

PatientsCost differences between Treatment A and BDifference in HAQ score between Treatment A and BICER per unit of improvement in HAQ over 6 monthsICER per 10% improvement in the HAQ over 6 months

Patient 1€6,4510.85€7,589€2,277
Patient 2€5,2180.65€8,028€2,408
Patient 3€5,4442.15€2,532€759.6
Patient 4€6,4891.00€6,489€1,947
Patient 5€5,3020.90€5,891€1,767
Patient 6€6,5361.05€6,225€1,868
Patient 7€6,4761.15€5,631€1,689
Patient 8€4,8912.30€2,127 €638.1
Patient 9€5,7051.30€4,388€1,316
Patient 10€6,5080.25€26,030€7,809
Patient 11€5,6491.50€3,766€1,130
Patient 12€6,3251.10€5,750€1,725
Patient 13€1,8021.50€1,201€360
Average€5,6001.20€6,588€1,977

The ICERs per unit improvement and per 10% improvement in the HAQ following 6 months of TNF-α inhibitor therapy.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.